NCI Cooperative Group Program in Need of an Overhaul

According to a recent study released by the Institute of Medicine (IOM), the NCI's clinical trials cooperative group program needs a major overhaul to conduct the type of large-scale clinical trials needed to improve cancer care. Since the program's inception, it has played a key role in developing and improving cancer treatments, and supports an average of 25,000 patients and 14,000 clinical investigators each year.

The IOM report, entitled A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the Cooperative Group Program, offered several suggestions to revamp the program.

The Cooperative Group Program shares one major obstacle with much of the cancer research world: a lack of funding. The NCI, facing a budget shortfall itself, currently provides $145 million to the program annually, which is inadequate to sustain the type of cross-institutional and interdisciplinary studies funded by the program.

The IOM report was more bad news for the program, following a survey by the American Society of Clinical Oncologists (ASCO) recently published in the Journal of Oncology Practice. That report stated that nearly one-third of NCI cooperative member sites plan to limit their participation in federally-funded clinical trials due to poor reimbursement rates.

Act Now - Urge Your Representatives to Support Increased Cancer Research Funding

--------------------------------------------------------------------------------

The president’s recently released budget proposal includes increases of just 3.2 percent for NIH and 3.16 percent for NCI. Advocates are urged to contact their legislators and urge them to increase both NIH and NCI’s budget by 13.5 percent; increases of $4.2 billion for NIH and $691 million for NCI. Please contact your elected official now!

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap